Retatrutide (LY3437943)
Investigational synthetic 39-amino-acid peptide triple hormone receptor agonist (GLP-1R, GIPR, GCGR) developed by Eli Lilly and Company (LY3437943). Under clinical evaluation for chronic weight management and type 2 diabetes.
60-Second Scientific Briefing
Retatrutide (LY3437943) is an investigational single peptide that stimulates GLP-1, GIP, and glucagon receptors. In Phase 2 clinical trials, it demonstrated up to 24.2% mean weight reduction at 48 weeks. It is currently undergoing Phase 3 evaluation (TRIUMPH program) and is NOT approved by the US FDA or international health authorities for commercial prescription.
What is Retatrutide?
Pharmacological Classification & Molecular IdentitySynthetic 39-amino-acid single peptide engineered with triple agonist activity at GLP-1, GIP, and glucagon receptors.
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Potent and balanced co-agonism at glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsInvestigational New Drug under Phase 3 clinical evaluation; NOT approved by the US FDA, European Medicines Agency, or Egyptian health authorities.
Retatrutide is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesCompleted randomized, double-blind, placebo-controlled Phase 2 trials in obesity (NEJM 2023) and type 2 diabetes (Lancet 2023); ongoing Phase 3 TRIUMPH clinical trials program.
Clinical Evidence
Completed randomized, double-blind, placebo-controlled Phase 2 trials in obesity (NEJM 2023) and type 2 diabetes (Lancet 2023); ongoing Phase 3 TRIUMPH clinical trials program.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesMost common adverse events in Phase 2 trials were gastrointestinal (nausea, diarrhea, vomiting, constipation). Dose-dependent increases in resting heart rate peaking at weeks 24-36, and transient cutaneous hyperesthesia/dysesthesia were observed.
Long-term cardiovascular morbidity/mortality outcomes, hepatic outcomes in MASH, and sustained weight maintenance off-treatment remain under investigation in Phase 3 trials.
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNOT ESTABLISHED. No approved commercial dose exists. Weekly subcutaneous doses in Phase 2 clinical trials ranged from 1 mg to 12 mg under experimental titration protocols.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Synthetic 39-amino-acid single peptide engineered with triple agonist activity at GLP-1, GIP, and glucagon receptors.
- Targets & Selectivity: Potent and balanced co-agonism at glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors.
- Completed randomized, double-blind, placebo-controlled Phase 2 trials in obesity (NEJM 2023) and type 2 diabetes (Lancet 2023); ongoing Phase 3 TRIUMPH clinical trials program.
- Safety considerations: Most common adverse events in Phase 2 trials were gastrointestinal (nausea, diarrhea, vomiting, constipation). Dose-dependent increases in resting heart rate peaking at weeks 24-36, and transient cutaneous hyperesthesia/dysesthesia were observed.
? Unknown / Under Ongoing Investigation
- Long-term cardiovascular morbidity/mortality outcomes, hepatic outcomes in MASH, and sustained weight maintenance off-treatment remain under investigation in Phase 3 trials.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysRetatrutide is classified as a Triple Incretin and Glucagon Receptor Agonist. Molecular structure: Synthetic 39-amino-acid single peptide engineered with triple agonist activity at GLP-1, GIP, and glucagon receptors..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023-08-10)
Retatrutide exerts biological activity via Potent and balanced co-agonism at glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (The Lancet, 2023-08-12)
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023-08-10)
Regulatory status: Investigational New Drug under Phase 3 clinical evaluation; NOT approved by the US FDA, European Medicines Agency, or Egyptian health authorities.
Investigational and research-only compounds cannot be legally distributed or marketed as prescription drugs.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) (ClinicalTrials.gov, 2023-06-29)
Clinical evaluation status: Completed randomized, double-blind, placebo-controlled Phase 2 trials in obesity (NEJM 2023) and type 2 diabetes (Lancet 2023); ongoing Phase 3 TRIUMPH clinical trials program.
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) (ClinicalTrials.gov, 2023-06-29)
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (The Lancet, 2023-08-12)
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023-08-10)
Reported safety profile: Most common adverse events in Phase 2 trials were gastrointestinal (nausea, diarrhea, vomiting, constipation). Dose-dependent increases in resting heart rate peaking at weeks 24-36, and transient cutaneous hyperesthesia/dysesthesia were observed.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023-08-10)
Key scientific uncertainties: Long-term cardiovascular morbidity/mortality outcomes, hepatic outcomes in MASH, and sustained weight maintenance off-treatment remain under investigation in Phase 3 trials.
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) (ClinicalTrials.gov, 2023-06-29)
NOT ESTABLISHED. No approved commercial dose exists. Weekly subcutaneous doses in Phase 2 clinical trials ranged from 1 mg to 12 mg under experimental titration protocols.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023-08-10)
Storage status: NOT ESTABLISHED. Commercial pharmaceutical labeling and final refrigerated storage specifications have not been issued by health authorities.
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) (ClinicalTrials.gov, 2023-06-29)
Yes. Unapproved pharmacological substances are strictly prohibited at all times in competitive sports under WADA Category S0 (Non-approved substances) or Category S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) (ClinicalTrials.gov, 2023-06-29)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023-08-10)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) ↗
https://clinicaltrials.gov/study/NCT05929066
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA ↗
https://doi.org/10.1016/S0140-6736(23)01053-X
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial ↗
https://www.nejm.org/doi/10.1056/NEJMoa2301972